Rajeev Saggar
Known title: Chief Medical OfficerCIK: 0001935638
Associated companies
Transaction History
| LQDA | ▲ Buy | Option Exercise | 50,000 | $187K | 8/19/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 50,000 | $3.7M | 8/19/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 29,534 | $2.3M | 8/17/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 703 | $50K | 7/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 9,223 | $660K | 7/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 4,487 | — | 7/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,531 | — | 7/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 9,220 | $354K | 4/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,531 | — | 4/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 4,486 | — | 4/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 35,365 | $1.3M | 3/13/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 32,955 | $0 | 1/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 21,142 | $791K | 1/12/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,531 | — | 1/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 17,945 | — | 1/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 4,918 | $133K | 11/5/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 66,463 | $1.8M | 11/5/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,327 | $125K | 10/13/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,530 | — | 10/10/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 20,000 | $557K | 8/28/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,526 | $37K | 7/21/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,327 | $76K | 7/14/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,531 | — | 7/11/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 7,597 | $129K | 6/4/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 17,654 | — | 6/3/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,450 | $33K | 4/21/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 3,714 | $50K | 4/14/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,445 | $32K | 1/21/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 6,249 | $74K | 1/14/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 71,780 | $0 | 1/11/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,526 | $28K | 10/18/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,260 | $25K | 10/14/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,873 | $21K | 7/19/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,470 | $18K | 7/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,649 | $23K | 4/19/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,525 | $22K | 4/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,654 | $26K | 3/18/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,876 | $93K | 3/18/2024 | View on chart |
| LQDA | ▲ Buy | Grant | 56,492 | $0 | 1/11/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 14,887 | $110K | 12/18/2023 | View on chart |
| LQDA | ▲ Buy | Grant | 83,333 | $0 | 1/11/2023 | View on chart |
| LQDA | ▲ Buy | Grant | 93,834 | $0 | 7/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.